dc.contributor.author | Masgala, Aikaterini | en |
dc.contributor.author | Bonovas, Stefanos | en |
dc.contributor.author | Nikolopoulos, Georgios K. | en |
dc.creator | Masgala, Aikaterini | en |
dc.creator | Bonovas, Stefanos | en |
dc.creator | Nikolopoulos, Georgios K. | en |
dc.date.accessioned | 2018-06-22T09:53:56Z | |
dc.date.available | 2018-06-22T09:53:56Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42104 | |
dc.description.abstract | Concurrent infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients positive for human immunodeficiency virus (HIV) is relatively common. The treatment of co-infected individuals is rather complex because the anti-viral therapy may be associated with drug-resistance, hepatotoxicity and lack of response. Herein, we present a summary of the available compounds and the recent recommendations concerning the therapeutic management of HIV/HBV and HIV/HCV co-infections. © 2012 Bentham Science Publishers. | en |
dc.language.iso | eng | en |
dc.source | Mini-Reviews in Medicinal Chemistry | en |
dc.subject | Article | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Anemia | en |
dc.subject | Bone marrow suppression | en |
dc.subject | Diarrhea | en |
dc.subject | Drug resistance | en |
dc.subject | Drug safety | en |
dc.subject | Fatigue | en |
dc.subject | Myalgia | en |
dc.subject | Nephrotoxicity | en |
dc.subject | Drug administration schedule | en |
dc.subject | Drug tolerability | en |
dc.subject | Fever | en |
dc.subject | Hemolytic anemia | en |
dc.subject | Human immunodeficiency virus infection | en |
dc.subject | Lamivudine | en |
dc.subject | Interferon-alpha | en |
dc.subject | Cell proliferation | en |
dc.subject | Vomiting | en |
dc.subject | Nausea | en |
dc.subject | Bone marrow toxicity | en |
dc.subject | Hiv infections | en |
dc.subject | Hepatitis c | en |
dc.subject | Treatment | en |
dc.subject | Drug withdrawal | en |
dc.subject | Pancreatitis | en |
dc.subject | Disease exacerbation | en |
dc.subject | Dizziness | en |
dc.subject | Headache | en |
dc.subject | Insomnia | en |
dc.subject | Asthenia | en |
dc.subject | Hyperpigmentation | en |
dc.subject | Gene expression | en |
dc.subject | Peginterferon | en |
dc.subject | Ribavirin | en |
dc.subject | Highly active antiretroviral therapy | en |
dc.subject | Hepacivirus | en |
dc.subject | Viral | en |
dc.subject | Skin manifestation | en |
dc.subject | Alpha2b interferon | en |
dc.subject | Recombinant proteins | en |
dc.subject | Hiv | en |
dc.subject | Antiretroviral therapy | en |
dc.subject | Highly active | en |
dc.subject | Hiv-1 | en |
dc.subject | Abnormal dreaming | en |
dc.subject | Adefovir dipivoxil | en |
dc.subject | Antiretrovirus agent | en |
dc.subject | Antiviral agents | en |
dc.subject | Asunaprevir | en |
dc.subject | Boceprevir | en |
dc.subject | Cd4 lymphocyte count | en |
dc.subject | Chronic hepatitis | en |
dc.subject | Co-infection | en |
dc.subject | Coinfection | en |
dc.subject | Coughing | en |
dc.subject | Daclatasvir | en |
dc.subject | Disease management | en |
dc.subject | Dna synthesis | en |
dc.subject | Drug sensitivity | en |
dc.subject | Drugs | en |
dc.subject | Dysgeusia | en |
dc.subject | Emtricitabine | en |
dc.subject | Emtricitabine plus tenofovir disoproxil | en |
dc.subject | Entecavir | en |
dc.subject | Hbv | en |
dc.subject | Hcv | en |
dc.subject | Hepatitis b | en |
dc.subject | Hepatitis b virus | en |
dc.subject | Human immunodeficiency virus infected patient | en |
dc.subject | Hypertransaminasemia | en |
dc.subject | Influenza | en |
dc.subject | Inosinate dehydrogenase | en |
dc.subject | Janus kinase | en |
dc.subject | Kidney failure | en |
dc.subject | Lamivudine plus tenofovir disoproxil | en |
dc.subject | Mental disease | en |
dc.subject | Mixed infection | en |
dc.subject | Molecular weight | en |
dc.subject | Myopathy | en |
dc.subject | Peginterferon alpha2a | en |
dc.subject | Peginterferon alpha2b | en |
dc.subject | Rna directed dna polymerase | en |
dc.subject | Src homology domain | en |
dc.subject | Telaprevir | en |
dc.subject | Telbivudine | en |
dc.subject | Tenofovir disoproxil | en |
dc.subject | Virus replication | en |
dc.subject | Efavirenz plus emtricitabine plus tenofovir disoproxil | fr |
dc.title | Recent advances in the treatment of HIV/HBV and HIV/HCV co-infection | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.2174/138955712800959062 | |
dc.description.volume | 12 | |
dc.description.issue | 9 | |
dc.description.startingpage | 890 | |
dc.description.endingpage | 904 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Nikolopoulos, Georgios K.[0000-0002-3307-0246] | |
dc.contributor.orcid | Bonovas, Stefanos [0000-0001-6102-6579] | |
dc.gnosis.orcid | 0000-0002-3307-0246 | |
dc.gnosis.orcid | 0000-0001-6102-6579 | |